HealthyDPFNCT01767272
Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers
A study testing fexofenadine in people with Healthy, run by Damanhour University.
Trial summary
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after oral administration. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- fexofenadine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- No sites listed yet
- Study dates
- Dec 2012to Jan 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- At least 18 years old and not more than 45 healthy male volunteers
- Actual weight no more than ± 30% from ideal body weight based on sex, height, and body frame
- Who had passed all the screening parameters
- Free of any drug exposure known to interfere with the pharmacokinetics or assay of fexofenadine for at least 10 days prior to the study
- Who had to be able to communicate effectively with study personnel, be literate, and able to give consent.
Who cannot join
- A clinically significant abnormal physical exam, medical history, or laboratory studies
- If they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a pulse rate of > 95 or < 50 beats/min at screening
- A history of serious intolerance, allergy, or sensitivity to fexofenadine
- The use of any prescription drug within the previous month or use of any over-the-counter medication (with the exception of acetaminophen) within the past 14 days
- A history of blood dyscrasias
- A history of alcohol or drug abuse within the past year
Show all 10Show fewer
- Donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study
- Unable to tolerate vein puncture and multiple blood samplings
- Any surgical/medical condition that might alter drug absorption, distribution, metabolism, or excretion
- Cannot follow instructions, in the opinion of the investigator.
About this study
Official title: Dose Proportionality of Fexofenadine
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after oral administration.
Read the detailed description
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after administration of single oral doses of 60 to 360 mg in an open-label, five-way crossover study.
- Conditions
- Healthy
- Being tested
- fexofenadine
- Keywords
- Fexofenadine, Pharmacokinetics, Bioavailability, Linearity, HPLC, Dose proportionality of fexofenadine in Egyptian volunteers
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fexofenadineDrug
Also called Telfast
fexofenadine brand name
| Study group | Role | What they receive |
|---|---|---|
| fexofenadine 60 mg | Other | First dose strength Receives: Drug: fexofenadine |
| fexofenadine 120 mg | Other | Second dose strength Receives: Drug: fexofenadine |
| fexofenadine 180 mg | Other | Third dose strength Receives: Drug: fexofenadine |
| fexofenadine 240 mg | Other | Fourth dose strength Receives: Drug: fexofenadine |
| fexofenadine 360 mg | Other | Fifth dose strength Receives: Drug: fexofenadine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tolerability
Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.
Measured: Participants will be followed for the duration of study, an expected average of 5 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2013 (estimated)
- Study startDec 2012
- Primary completionJan 2013
- Study completionJan 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- Damanhour University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sally Helmy, PhD, CPHQ, Damanhour University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01767272
- Sponsor's protocol ID
- PPT2
- Acronym
- DPF
- Status last verified
- Jan 2013
- First submitted
- 9 Jan 2013
- Last updated
- 14 Jan 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose Proportionality of Fexofenadine
- ClinicalTrials.gov ID
- NCT01767272
- Acronym / sponsor ID
- DPF / PPT2
- Conditions
- Healthy
- Keywords
- Fexofenadine, Pharmacokinetics, Bioavailability, Linearity, HPLC, Dose proportionality of fexofenadine in Egyptian volunteers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- Damanhour UniversityUniversity, hospital or other
- Study start
- Dec 2012
- Primary completion
- Jan 2013 (actual)
- Study completion
- Jan 2013 (actual)
- First posted
- 14 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after oral administration.
Detailed description
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after administration of single oral doses of 60 to 360 mg in an open-label, five-way crossover study.
Study design
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| fexofenadine 60 mg | Other | Drug: fexofenadineFirst dose strength |
| fexofenadine 120 mg | Other | Drug: fexofenadineSecond dose strength |
| fexofenadine 180 mg | Other | Drug: fexofenadineThird dose strength |
| fexofenadine 240 mg | Other | Drug: fexofenadineFourth dose strength |
| fexofenadine 360 mg | Other | Drug: fexofenadineFifth dose strength |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- At least 18 years old and not more than 45 healthy male volunteers
- Actual weight no more than ± 30% from ideal body weight based on sex, height, and body frame
- Who had passed all the screening parameters
- Free of any drug exposure known to interfere with the pharmacokinetics or assay of fexofenadine for at least 10 days prior to the study
- Who had to be able to communicate effectively with study personnel, be literate, and able to give consent.
Key exclusion criteria (10 listed)
- A clinically significant abnormal physical exam, medical history, or laboratory studies
- If they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a pulse rate of > 95 or < 50 beats/min at screening
- A history of serious intolerance, allergy, or sensitivity to fexofenadine
- The use of any prescription drug within the previous month or use of any over-the-counter medication (with the exception of acetaminophen) within the past 14 days
- A history of blood dyscrasias
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fexofenadineAlso: Telfastfexofenadine brand name | Drug | fexofenadine 120 mg, fexofenadine 180 mg, fexofenadine 240 mg, fexofenadine 360 mg, fexofenadine 60 mg |
Primary outcome
Tolerability
Time frame: Participants will be followed for the duration of study, an expected average of 5 weeks.
Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2013.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing fexofenadine in people with Healthy, run by Damanhour University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tolerability (time frame: Participants will be followed for the duration of study, an expected average of 5 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2013.